Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713256 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
A Phase 2 study of Graves Disease, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT02713256: Completed Phase 2 study of Graves Disease, sponsored by Novartis Pharmaceuticals.
NCT02713256 is a Phase 2 study of Graves Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 15 participants, below the 308-participant average among 11 other Graves Disease trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02713256, a Phase 2 study of Graves Disease, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease
Primary Outcome
Normalization of TSH is defined as TSH level greater than 0.35 mU/L after 12 week treatment (Day 85)
Conditions Studied
Interventions
- DRUG CFZ533
Study Locations (3)
Hawaii
- Novartis Investigative Site - Honolulu
Minnesota
- Novartis Investigative Site - Rochester
Other
- Novartis Investigative Site - Mainz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-04-19 |
| Est. Completion | 2017-04-24 |
| Phase | Phase 2 |
What the finished NCT02713256 record still lists
NCT02713256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 308-participant average among 11 other Graves Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Graves Disease appearing as the primary indexed condition, and to 1 intervention - of which CFZ533 is the first listed.
NCT02713256 reports a single indexed study location in Hawaii, Minnesota, Other.
Frequently Asked Questions
What is clinical trial NCT02713256 about?
NCT02713256 is a clinical study titled "A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease". An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease
What is the current status of trial NCT02713256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2016-04-19. Estimated completion is 2017-04-24.
What conditions does trial NCT02713256 study?
This clinical trial studies the following conditions: Graves Disease.
What interventions are being tested in trial NCT02713256?
The interventions under investigation include: CFZ533 (DRUG).
Who is sponsoring clinical trial NCT02713256?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02713256 being conducted?
This trial has 3 study locations across Hawaii, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graves Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02713256's enrollment target sits among peer trials
15 10th of 11 higher than 1 of 11 other Graves Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graves Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
RECRUITING · Phase 2
-
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
RECRUITING · Phase 2
-
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
RECRUITING · Phase 2
-
Radioactive Iodide Therapy for Pediatric Graves' Disease
COMPLETED · Phase 2
-
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
RECRUITING · Phase 1
-
Study of BHV-1300 in Graves' Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI